Imagine a coffee machine for medicine that makes a pill exactly right for your specific body, age, or weight. Instead of everyone taking the same standard dose, this system prints custom pills on the spot. It uses a smart library of ingredients to ensure every dose is safe and precise.
Standard drug dosages often fail children and the elderly due to metabolic and genetic differences. There has been no practical, industry-standard way to manufacture these personalized doses at scale within pharmacies.
A certified 3D printing system (PharmaKit/MiniLab) and a cloud-based management platform (Curify 2.0) with integrated quality control tools.
If you are a pharmacy chain dealing with the difficulty of compounding custom doses for elderly patients — this project developed the PharmaKit technology that brings industry-level standards to mass customization of medicines on-site.
If you are a hospital dealing with the lack of precise drug dosages for children — this project developed a certified 3D printing platform that allows for high-precision dosing tailored to the patient's metabolic needs.
If you are a tech provider dealing with the need for remote medicine management — this project developed the Curify 2.0 platform on Google Cloud for real-time monitoring and remote management of drug printers.
Based on available project data, specific pricing or cost details for the hardware and software are not provided.
The project established a standardized development process that reduced formulation lead times from several months to one to two months, enabling the library to grow to over 70 validated formulations.
Based on available project data, specific patent or licensing terms are not mentioned, though the technology is developed by CurifyLabs Oy.
Yes, the technology platform achieved ISO 13485 certification in June 2024, confirming its readiness for clinical use.
The system uses a precision weighing scale for 100% in-process verification and near-infrared spectroscopy models to ensure blend uniformity.
The project is led by a single SME, CurifyLabs Oy from Finland, which holds 100% of the industry ratio. This lean structure indicates a highly focused commercial drive, as the company manages both the hardware (PharmaPrinter) and software (Curify 2.0) development internally.
Contact CurifyLabs Oy in Finland for licensing or partnership inquiries.
Contact SciTransfer to explore integration of 3D drug printing into your pharmacy network.
